{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:54:41Z","timestamp":1790362481816,"version":"4.1.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Triplet therapy with darolutamide, androgen deprivation therapy, and docetaxel (DOC) has emerged as an intensified treatment option for metastatic castration-sensitive prostate cancer (mCSPC). This study evaluated real-world prostate specific antigen (PSA) responses and adverse events (AEs) associated with triplet therapy, with a focus on age-specific differences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective cohort study across six academic institutions in Japan between February 2023 and February 2025. A total of 137 patients with mCSPC who received triplet therapy were analyzed. PSA responses and AEs were assessed, including subgroup analyses by age (&amp;lt;75 vs \u226575\u00a0years).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median age was 71\u00a0years, and 40 patients (29.2%) were aged \u226575\u00a0years. Six cycles of DOC were completed at similar rates in patients aged &amp;lt;75\u00a0years (66.0%) and\u00a0\u2265\u00a075\u00a0years (57.5%) (P\u00a0=\u00a0.435). The median baseline PSA was 298\u00a0ng\/ml, and 107 patients (78.1%) met the CHAARTED high-volume criteria. At three months, the median [interquartile range] PSA decline was 99.8% [99.0\u201399.9]; 113 patients (92.6%) achieved a PSA decline &amp;gt;90%, and 35 patients (28.7%) achieved a PSA &amp;lt;0.2\u00a0ng\/ml. During follow-up, the proportion achieving a PSA nadir &amp;lt;0.2\u00a0ng\/ml did not differ significantly between patients aged &amp;lt;75\u00a0years (63.9%) and\u00a0\u2265\u00a075\u00a0years (55.0%) (P\u00a0=\u00a0.341). Grade\u00a0\u2265\u00a03 AEs occurred in 56 patients (40.9%), including febrile neutropenia in 29 patients (21.2%). The incidence of AEs did not differ significantly by age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this real-world cohort, triplet therapy showed substantial PSA declines and acceptable tolerability, with no significant differences in short-term efficacy or safety between patients aged &amp;lt;75 and\u00a0\u2265\u00a075\u00a0years. These findings suggest that chronological age alone should not preclude consideration of triplet therapy in appropriately selected patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyag011","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T12:27:43Z","timestamp":1768307263000},"page":"628-635","source":"Crossref","is-referenced-by-count":2,"title":["Age-stratified clinical outcomes and adverse events in patients with metastatic castration-sensitive prostate cancer receiving triplet therapy with darolutamide, androgen deprivation therapy, and docetaxel"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5200-9053","authenticated-orcid":false,"given":"Taizo","family":"Uchimoto","sequence":"first","affiliation":[{"name":"Department of Urology, Osaka Medical and Pharmaceutical University , 2-7 Daigaku-machi, Takatsuki City, Osaka 569-8686 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Hirosuna","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka Medical and Pharmaceutical University , 2-7 Daigaku-machi, Takatsuki City, Osaka 569-8686 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heima","family":"Niigawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Kawasaki Medical School , 577, Matsushima, Kurashiki City, Okayama 701-0192 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Jo","sequence":"additional","affiliation":[{"name":"Department of Urology, Kawasaki Medical School , 577, Matsushima, Kurashiki City, Okayama 701-0192 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Morinaka","sequence":"additional","affiliation":[{"name":"Department of Urology, Kawasaki Medical School , 577, Matsushima, Kurashiki City, Okayama 701-0192 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Fukuokaya","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishi-shimbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhiko","family":"Yoshizawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Fujita-Health University School of Medicine , Nagoya, 1-98 Dengakugakubo, Kutsukake, Toyoake City, Aichi 470-1192 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Saruta","sequence":"additional","affiliation":[{"name":"Department of Urology, Fujita-Health University School of Medicine , Nagoya, 1-98 Dengakugakubo, Kutsukake, Toyoake City, Aichi 470-1192 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Urology, Kindai University Faculty of Medicine , Osaka, 377-2, Oono-higashi, Osakasayama City, Osaka 589-8511 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saizo","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Kindai University Faculty of Medicine , Osaka, 377-2, Oono-higashi, Osakasayama City, Osaka 589-8511 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Kindai University Faculty of Medicine , Osaka, 377-2, Oono-higashi, Osakasayama City, Osaka 589-8511 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritoshi","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka Medical and Pharmaceutical University , 2-7 Daigaku-machi, Takatsuki City, Osaka 569-8686 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka Medical and Pharmaceutical University , 2-7 Daigaku-machi, Takatsuki City, Osaka 569-8686 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Maenosono","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka Medical and Pharmaceutical University , 2-7 Daigaku-machi, Takatsuki City, Osaka 569-8686 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Tsujino","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka Medical and Pharmaceutical University , 2-7 Daigaku-machi, Takatsuki City, Osaka 569-8686 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyosuke","family":"Nishio","sequence":"additional","affiliation":[{"name":"Department of Urology, Kawasaki Medical School , 577, Matsushima, Kurashiki City, Okayama 701-0192 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Yoshikawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka Medical and Pharmaceutical University , 2-7 Daigaku-machi, Takatsuki City, Osaka 569-8686 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Ichihashi","sequence":"additional","affiliation":[{"name":"Department of Urology, Kawasaki Medical School , 577, Matsushima, Kurashiki City, Okayama 701-0192 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2599-8183","authenticated-orcid":false,"given":"Fumihiko","family":"Urabe","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishi-shimbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishi-shimbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Yanagisawa","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishi-shimbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6164-4684","authenticated-orcid":false,"given":"Shunsuke","family":"Tsuzuki","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishi-shimbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4766-2074","authenticated-orcid":false,"given":"Kiyoshi","family":"Takahara","sequence":"additional","affiliation":[{"name":"Department of Urology, Fujita-Health University School of Medicine , Nagoya, 1-98 Dengakugakubo, Kutsukake, Toyoake City, Aichi 470-1192 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruo","family":"Inamoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Hamamatsu University School of Medicine , Osaka, 1-20-1 Handayama, Chuo-ku, Hamamatsu, Shizuoka 431-3192 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Urology, Kindai University Faculty of Medicine , Osaka, 377-2, Oono-higashi, Osakasayama City, Osaka 589-8511 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhito","family":"Azuma","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka Medical and Pharmaceutical University , 2-7 Daigaku-machi, Takatsuki City, Osaka 569-8686 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5673-1553","authenticated-orcid":false,"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishi-shimbashi, Minato-ku, Tokyo 105-8461 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4157-1929","authenticated-orcid":false,"given":"Kazumasa","family":"Komura","sequence":"additional","affiliation":[{"name":"Department of Urology, Kawasaki Medical School , 577, Matsushima, Kurashiki City, Okayama 701-0192 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"2026050705070534700_ref1","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"2026050705070534700_ref2","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"2026050705070534700_ref3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"2026050705070534700_ref4","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026050705070534700_ref5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"2026050705070534700_ref6","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet."},{"key":"2026050705070534700_ref7","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"2026050705070534700_ref8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10147-024-02649-2","article-title":"Predicting time to castration resistance with androgen-receptor signaling inhibitors in hormone-sensitive prostate cancer: data from ULTRA-Japan consortium","volume":"30","author":"Uchimoto","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"2026050705070534700_ref9","doi-asserted-by":"publisher","first-page":"102140","DOI":"10.1016\/j.clgc.2024.102140","article-title":"Clinical outcomes and risk stratification in patients with metastatic hormone-sensitive prostate cancer treated with new-generation androgen receptor Signaling inhibitors","volume":"22","author":"Suzuki","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"2026050705070534700_ref10","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.euo.2023.12.013","article-title":"Clinical outcomes of patients with high-risk metastatic hormone-naive prostate cancer: a 3-year interim analysis of the observational J-ROCK study","volume":"7","author":"Miyake","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"2026050705070534700_ref11","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/pros.24813","article-title":"Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone-sensitive prostate cancer: a multicenter study","volume":"85","author":"Yanagisawa","year":"2025","journal-title":"Prostate."},{"key":"2026050705070534700_ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.10.001","article-title":"Age-related efficacy and safety of Darolutamide plus androgen-deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer: a subgroup analysis of the phase 3 ARASENS trial. Eur","author":"Carles","year":"2025","journal-title":"Urol Oncol"},{"key":"2026050705070534700_ref13","doi-asserted-by":"publisher","first-page":"e70029","DOI":"10.1002\/cam4.70029","article-title":"Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: phase 3 ARASENS subgroup analysis","volume":"13","author":"Uemura","year":"2024","journal-title":"Cancer Med"},{"key":"2026050705070534700_ref14","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1093\/jjco\/hyae098","article-title":"Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter study","volume":"54","author":"Urabe","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"2026050705070534700_ref15","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1111\/iju.70154","article-title":"Preliminary report on the efficacy and safety of triplet therapy in patients with metastatic hormone-sensitive prostate cancer: YUSHIMA study","volume":"32","author":"Yasuda","year":"2025","journal-title":"Int J Urol"},{"key":"2026050705070534700_ref16","doi-asserted-by":"crossref","first-page":"320","DOI":"10.5694\/j.1326-5377.1964.tb115781.x","article-title":"Declaration of Helsinki","volume":"2","author":"Gandevia","year":"1964","journal-title":"Med J Aust"},{"key":"2026050705070534700_ref17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026050705070534700_ref18","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026050705070534700_ref19","doi-asserted-by":"crossref","first-page":"1599292","DOI":"10.3389\/or.2025.1599292","article-title":"Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach","volume":"19","author":"Zapatero","year":"2025","journal-title":"Oncol Rev"},{"key":"2026050705070534700_ref20","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1007\/s11255-025-04465-7","article-title":"Short-term outcomes of triplet therapy in metastatic hormone-sensitive prostate cancer in older adults: a retrospective, single-center real-world cohort study","volume":"57","author":"Usui","year":"2025","journal-title":"Int Urol Nephrol"},{"key":"2026050705070534700_ref21","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.clgc.2023.12.018","article-title":"Real-world evidence of triplet therapy in metastatic hormone-sensitive prostate cancer: an Austrian Multicenter study","volume":"22","author":"Kafka","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"2026050705070534700_ref22","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1007\/s00520-014-2328-7","article-title":"Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer","volume":"22","author":"Shiota","year":"2014","journal-title":"Support Care Cancer"},{"key":"2026050705070534700_ref23","first-page":"1721","article-title":"Efficacy of primary prophylaxis with Pegfilgrastim after docetaxel for castration-resistant prostate cancer","volume":"46","author":"Koutake","year":"2019","journal-title":"Gan To Kagaku Ryoho"},{"key":"2026050705070534700_ref24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.prnil.2024.11.003","article-title":"Comparative adverse event profiles of triplet therapy versus docetaxel-based therapy in patients with metastatic prostate cancer: a multicenter retrospective study","volume":"13","author":"Urabe","year":"2025","journal-title":"Prostate Int"},{"key":"2026050705070534700_ref25","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1007\/s10147-012-0443-3","article-title":"Reduced-dose docetaxel for castration-resistant prostate cancer has no inferior impact on overall survival in Japanese patients","volume":"18","author":"Kita","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"2026050705070534700_ref26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10147-012-0510-9","article-title":"Clinical outcomes by relative docetaxel dose and dose intensity as chemotherapy for Japanese patients with castration-resistant prostate cancer: a retrospective multi-institutional collaborative study","volume":"19","author":"Kamiya","year":"2014","journal-title":"Int J Clin Oncol"},{"key":"2026050705070534700_ref27","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12885-019-5342-9","article-title":"The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients","volume":"19","author":"Terada","year":"2019","journal-title":"BMC Cancer"},{"key":"2026050705070534700_ref28","doi-asserted-by":"publisher","first-page":"4575","DOI":"10.21873\/anticanres.17803","article-title":"Real-world outcomes of Enfortumab Vedotin in elderly patients with metastatic urothelial carcinoma","volume":"45","author":"Nishio","year":"2025","journal-title":"Anticancer Res"},{"key":"2026050705070534700_ref29","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.euo.2023.11.012","article-title":"Clinical outcomes of enzalutamide in metastatic hormone-sensitive prostate cancer in patients aged &lt;75 and &gt;\/=75 years: ARCHES post hoc analysis","volume":"7","author":"Gomez-Veiga","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"2026050705070534700_ref30","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1111\/jgs.19045","article-title":"Treatment patterns and oncological outcomes of older adults with metastatic prostate cancer in real-world setting","volume":"72","author":"Wenzel","year":"2024","journal-title":"J Am Geriatr Soc"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/5\/628\/66728418\/hyag011.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/5\/628\/66728418\/hyag011.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T09:07:15Z","timestamp":1778144835000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/5\/628\/8456493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,2,3]]},"published-print":{"date-parts":[[2026,5,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag011","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,2,3]]}}}